{"id":37647,"date":"2022-06-05T14:30:03","date_gmt":"2022-06-05T14:30:03","guid":{"rendered":"https:\/\/harchi90.com\/trastuzumab-deruxtecan-in-previously-treated-her2-low-advanced-breast-cancer\/"},"modified":"2022-06-05T14:30:03","modified_gmt":"2022-06-05T14:30:03","slug":"trastuzumab-deruxtecan-in-previously-treated-her2-low-advanced-breast-cancer","status":"publish","type":"post","link":"https:\/\/harchi90.com\/trastuzumab-deruxtecan-in-previously-treated-her2-low-advanced-breast-cancer\/","title":{"rendered":"Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer"},"content":{"rendered":"
\n

From the Memorial Sloan Kettering Cancer Center, New York (SM); Institut du Cancer de Montpellier, Universit\u00e9 Montpellier, INSERM Unit\u00e9 1194, Montpellier (WJ), and Institut Curie, Universit\u00e9 Paris Cit\u00e9, Paris (J.-YP) – both in France; Kanagawa Cancer Center, Yokohama (TY), Kyushu Cancer Center, National Hospital Organization, Fukuoka (ET), Showa University Hospital, Tokyo (JT), and Tokai University School of Medicine, Isehara-shi (NN) – all in Japan; Yonsei Cancer Center, Yonsei University Health System (J. Sohn), Samsung Medical Center (YHP), Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul National University (S.-AI), and Asan Medical Center, University of Ulsan College of Medicine (S.-BK), Seoul, Kyungpook National University Chilgok Hospital, Daegu (YSC), and the National Cancer Center, Goyang-si (KSL) – all in South Korea; the Department of Medical Oncology, Hospital Cl\u00ednic de Barcelona (MV, AP), Translational Genomics and Targeted Therapies in Solid Tumors, Institut d’Investigacions Biom\u00e8diques August Pi i Sunyer (AP), the Department of Medicine, University of Barcelona (AP), the Breast Cancer Unit, Institute of Oncology (IOB) \u2013Quir\u00f3n Salud (AP), Institut Catala d’Oncologia l’Hospitalet \u2013 Hospital Duran i Reynals (MG-G.), and Vall d’Hebron University Hospital, Vall d’Hebron Institute of Oncology (CS) – all in Barcelona; the University of Texas MD Anderson Cancer Center, Houston (NTU); Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing (BX), Zhejiang Cancer Hospital, Hangzhou (XW), the First Hospital of Jilin University, Changchun (WL), Sun Yat-sen Memorial Hospital, Sun Yat- sen University, Guangzhou (QL), West China Hospital, Sichuan University, Chengdu (TL), and Liaoning Cancer Hospital and Institute, Shenyang (TS) – all in China; the Cleveland Clinic Foundation, Cleveland (HCFM); the University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center, San Francisco (HSR); Rabin Medical Center, Petah Tikva, Tel Aviv University, Tel Aviv, Israel (RY); Alexandra Regional General Hospital, Athens (FZ); Institut Jules Bordet, Brussels (AG); Queen Mary University of London, London (PS), and Edinburgh Cancer Center, Institute of Genetics and Cancer, University of Edinburgh, Edinburgh (DAC) – both in the United Kingdom; Daiichi Sankyo, Basking Ridge, NJ (DG, LY, YW, J. Singh, PV, GM); and the Breast Center, Department of Obstetrics and Gynecology, and Comprehensive Cancer Center Munich, Ludwig Maximilian University Hospital, Munich, Germany (NH).<\/p>\n<\/div>\n

Dr. Modi can be contacted at [email\u00a0protected]<\/span> or at the Memorial Sloan Kettering Cancer Center, 1275 York Ave., New York, NY 10065.<\/p>\n","protected":false},"excerpt":{"rendered":"

From the Memorial Sloan Kettering Cancer Center, New York (SM); Institut du Cancer de Montpellier, Universit\u00e9 Montpellier, INSERM Unit\u00e9 1194, Montpellier (WJ), and Institut Curie, Universit\u00e9 Paris Cit\u00e9, Paris (J.-YP) – both in France; Kanagawa Cancer Center, Yokohama (TY), Kyushu Cancer Center, National Hospital Organization, Fukuoka (ET), Showa University Hospital, Tokyo (JT), and Tokai University …<\/p>\n

Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer<\/span> Read More »<\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"default","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","spay_email":"","jetpack_publicize_message":"","jetpack_is_tweetstorm":false,"jetpack_publicize_feature_enabled":true},"categories":[8],"tags":[],"jetpack_featured_media_url":"","jetpack_publicize_connections":[],"jetpack_sharing_enabled":true,"fifu_image_url":"https:\/\/www.nejm.org\/na101\/home\/literatum\/publisher\/mms\/journals\/content\/nejm\/0\/nejm.ahead-of-print\/nejmoa2203690\/20220603\/images\/img_small\/nejmoa2203690_f1.jpeg","_links":{"self":[{"href":"https:\/\/harchi90.com\/wp-json\/wp\/v2\/posts\/37647"}],"collection":[{"href":"https:\/\/harchi90.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/harchi90.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/harchi90.com\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/harchi90.com\/wp-json\/wp\/v2\/comments?post=37647"}],"version-history":[{"count":0,"href":"https:\/\/harchi90.com\/wp-json\/wp\/v2\/posts\/37647\/revisions"}],"wp:attachment":[{"href":"https:\/\/harchi90.com\/wp-json\/wp\/v2\/media?parent=37647"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/harchi90.com\/wp-json\/wp\/v2\/categories?post=37647"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/harchi90.com\/wp-json\/wp\/v2\/tags?post=37647"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}